XNAS · Healthcare · Biotechnology
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.39 | -0.16 | +58.97% | $162.1M | ✅ Beat | -1.67% | -0.15% | — |
| 2026-02-23 | Q4 2025 | -0.07 | -0.20 | -185.71% | $151.7M | ❌ Miss | +9.21% | +11.27% | -3.78% |
| 2025-11-04 |
| Q3 2025 |
| -0.34 |
| -0.30 |
| +11.76% |
| $118.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.35 | -0.48 | -37.14% | $102.7M | ❌ Miss | +8.74% | +26.61% | +38.40% |
| 2025-02-25 | Q4 2024 | -0.82 | -0.60 | +26.83% | $66.4M | ✅ Beat | +3.08% | +7.77% | +22.67% |
| 2024-11-13 | Q3 2024 | -0.94 | -0.61 | +35.11% | $48.1M | ✅ Beat | +0.31% | +0.16% | +12.89% |
| 2024-05-08 | Q1 2024 | -1.20 | -1.01 | +15.83% | $27.6M | ✅ Beat | -8.86% | +3.08% | -13.79% |
| 2024-02-27 | Q4 2023 | -1.36 | -1.31 | +3.68% | $13.1M | ✅ Beat | — | — | — |
Showing last 8 quarters.